Compare Viatris Inc (VTRS) vs Vanguard Growth Index Fund ETF (VUG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Viatris Inc vs Vanguard Growth Index Fund ETF — how do they compare? Viatris Inc trades at $17.54 (market cap $19.79B), while Vanguard Growth Index Fund ETF trades at $86.11. The key difference: Viatris Inc pays a 2.83% dividend while Vanguard Growth Index Fund ETF pays none, and Viatris Inc is trading nearer its 52-week high, Vanguard Growth Index Fund ETF nearer its low. Which is the better fit depends on your goals.
| VTRS | VUG | |
|---|---|---|
Market Cap | $19.79B | — |
Sector | Health | Sector/Thematic |
52-Week High | $17.39 | $90.29 |
52-Week Low | $8.74 | $70.00 |
Enterprise Value | $32.00B | — |
Dividend Yield | 2.83% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Viatris (VTRS) trades at $17.59, up 1.74% today, with a bullish technical signal and consistent earnings beats in recent quarters. The company reported revenue of $14.3B for 2025 but posted a net loss of $3.51B, reflecting margin pressures. Positive pipeline developments include FDA acceptance of a new drug application for fast-acting meloxicam, with a PDUFA date set for December 2026. Cash flow from operations remains strong at $2.32B, supporting debt reduction efforts.
The outlook is mixed: analyst consensus targets $20.00 (13.7% upside), but profitability challenges and high debt levels pose risks. Investment appeal hinges on successful pipeline execution and margin recovery, while competitive and regulatory pressures in the generics market remain key watchpoints for shareholders.
VUG trades at $85.32, up 0.06% on the day, with technical indicators showing a bearish bias as moving averages signal selling pressure while oscillators remain neutral. The ETF's growth-focused strategy, concentrated in large-cap U.S. companies, benefits from a low expense ratio of 0.03% and a decade-long track record of strong returns, though key financial ratios are not disclosed in the provided data. Recent news highlights its appeal for long-term investors seeking exposure to growth stocks.
The outlook for VUG is mixed, with technical weakness offset by positive sentiment for long-term growth potential. Risks include high tech concentration and market volatility, but analyst coverage emphasizes its cost efficiency and diversification benefits for buy-and-hold strategies.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →About Vanguard Growth Index Fund ETF
VUG is an index-based ETF that tracks the CRSP US Large Cap Growth Index, providing concentrated exposure to the largest and fastest-growing companies in the United States. It focuses on stocks with high growth potential across tech, communication, and consumer sectors, serving as a low-cost, high-conviction core holding for long-term capital appreciation.
Read more on VUG →
